BACKGROUND AND PURPOSE: Primary stroke centers (PSC) have demonstrated improved survival in patients with acute ischemic stroke (AIS). The objective of this study was to evaluate the cost-effectiveness of treating AIS patients in a PSC compared with a nonPSC hospital setting. METHODS: We developed a decision analytic model to project the lifetime outcomes and costs of 2 hypothetical cohorts of 75 AIS patients. Clinical data were derived from a recent observational study comparing PSC- and nonPSC-admitted patients, clinical trials, longitudinal cohort studies, and health state preference studies. Cost data were based on Medicare reimbursement and other published sources. We used a healthcare payer perspective, and the primary outcomes were incremental life expectancy, quality-adjusted life years, and healthcare costs. We performed sensitivity and scenario analyses to evaluate uncertainty in the results. RESULTS: Admission to a PSC resulted in a gain of 0.22 years of life (95% credible range [CR], 0.12-0.33) and 0.15 quality-adjusted life years (95% CR, 0.08-0.23) per patient, at a cost of $3600 (95% CR, $2400-$5000) per patient, compared with admission to a nonPSC hospital. The incremental cost/quality-adjusted life year gained was $24 000, and all probabilistic simulation results were below the $100 000/quality-adjusted life year threshold. In scenario analyses accounting for as few as 7 and as many as 500 AIS patients/year per PSC, cost-effectiveness improved as the number of AIS patients admitted per year increased. CONCLUSIONS: Our study indicates that care at a PSC for patients with AIS is cost-effective and improves outcomes across a wide range of possible scenarios.
BACKGROUND AND PURPOSE:Primary stroke centers (PSC) have demonstrated improved survival in patients with acute ischemic stroke (AIS). The objective of this study was to evaluate the cost-effectiveness of treating AISpatients in a PSC compared with a nonPSC hospital setting. METHODS: We developed a decision analytic model to project the lifetime outcomes and costs of 2 hypothetical cohorts of 75 AISpatients. Clinical data were derived from a recent observational study comparing PSC- and nonPSC-admitted patients, clinical trials, longitudinal cohort studies, and health state preference studies. Cost data were based on Medicare reimbursement and other published sources. We used a healthcare payer perspective, and the primary outcomes were incremental life expectancy, quality-adjusted life years, and healthcare costs. We performed sensitivity and scenario analyses to evaluate uncertainty in the results. RESULTS: Admission to a PSC resulted in a gain of 0.22 years of life (95% credible range [CR], 0.12-0.33) and 0.15 quality-adjusted life years (95% CR, 0.08-0.23) per patient, at a cost of $3600 (95% CR, $2400-$5000) per patient, compared with admission to a nonPSC hospital. The incremental cost/quality-adjusted life year gained was $24 000, and all probabilistic simulation results were below the $100 000/quality-adjusted life year threshold. In scenario analyses accounting for as few as 7 and as many as 500 AISpatients/year per PSC, cost-effectiveness improved as the number of AISpatients admitted per year increased. CONCLUSIONS: Our study indicates that care at a PSC for patients with AIS is cost-effective and improves outcomes across a wide range of possible scenarios.
Authors: Kit N Simpson; Annie N Simpson; Patrick D Mauldin; Michael D Hill; Sharon D Yeatts; Judith A Spilker; Lydia D Foster; Pooja Khatri; Renee Martin; Edward C Jauch; Dawn Kleindorfer; Yuko Y Palesch; Joseph P Broderick Journal: Stroke Date: 2014-05-13 Impact factor: 7.914
Authors: Maarten M H Lahr; Durk-Jouke van der Zee; Gert-Jan Luijckx; Patrick C A J Vroomen; Erik Buskens Journal: BMC Med Res Methodol Date: 2017-01-10 Impact factor: 4.615
Authors: Anne-Claire Peultier; William K Redekop; Michael Allen; Jaime Peters; Omer Faruk Eker; Johan L Severens Journal: Stroke Date: 2019-10-22 Impact factor: 7.914
Authors: Sushanth Rao Aroor; Kaiz S Asif; Jennifer Potter-Vig; Arun Sharma; Bijoy K Menon; Violiza Inoa; Cynthia B Zevallos; Jose G Romano; Santiago Ortega-Gutierrez; Larry B Goldstein; Dileep R Yavagal Journal: J Stroke Date: 2022-01-31 Impact factor: 6.967
Authors: Roel D Freriks; Jochen O Mierau; Erik Buskens; Elena Pizzo; Gert-Jan Luijckx; Durk-Jouke van der Zee; Maarten M H Lahr Journal: BMC Health Serv Res Date: 2020-02-10 Impact factor: 2.655
Authors: Nawaraj Bhattarai; Christopher I Price; Peter McMeekin; Mehdi Javanbakht; Luke Vale; Gary A Ford; Lisa Shaw Journal: Int J Stroke Date: 2021-04-07 Impact factor: 5.266